ACA
SLDB icon

Avoro Capital Advisors’s Solid Biosciences SLDB Stock Holding History

Avoro Capital Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-18,333
Closed -$2.06M – 55
2018
Q1 		$2.06M Buy
+18,333
New +$6.19M 0.1% 46

Other funds holding SLDB

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Avoro Capital Advisors's SLDB Position: Q2 2018 in Review

Avoro Capital Advisors sold out of Solid Biosciences (SLDB) in Q2 2018, closing a stake of 18,333 shares — an estimated $2.06M sold.

Avoro Capital Advisors first reported a position in SLDB in Q1 2018 and held it in 1 quarter. The position peaked at $2.06M in Q1 2018. 64 funds tracked by Wall St. Rank hold SLDB as of Q2 2018.

  • Avoro Capital Advisors reported no remaining Solid Biosciences position as of Q2 2018 after selling out during the quarter.
  • Avoro Capital Advisors sold 18,333 Solid Biosciences shares in Q2 2018, an estimated $2.06M.
  • Avoro Capital Advisors first reported a position in Solid Biosciences in Q1 2018 and held it in 1 quarter.
  • Avoro Capital Advisors's Solid Biosciences position peaked at $2.06M in Q1 2018.
  • 64 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2018.

Based on Avoro Capital Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.